The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.

Akinci B, Meral R, Rus D, Hench R, Neidert AH, DiPaola F, Westerhoff M, Taylor SI, Oral EA

Endocrinology, diabetes & metabolism case reports1 Jan 2020Cited by 10 (Europe PMC)

PMID32213649PMCIDPMC7159256DOI10.1530/edm-19-0139PepBankPUB-32213649

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanCase report or seriesEfficacy outcome
In a patient with atypical partial lipodystrophy, hunger scales decreased slightly during setmelanotide treatment.
In plain wordsIn a patient with atypical lipodystrophy, hunger decreased slightly from before setmelanotide treatment.
Peptide
Setmelanotide
Outcome
DecreaseHunger
Study
n = 1
Comparator
Before setmelanotide
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Although there was a slight decrease in hunger scales and visceral fat, stimulating melanocortin-4 receptor by setmelanotide did not result in any other metabolic benefit such as improvement of hypertriglyceridemia or diabetes control as desired.
1 context sentence(design, population, supporting numbers)
Summary · context
A patient with atypical partial lipodystrophy who had a transient initial response to metreleptin experienced acute worsening of her metabolic state when neutralizing antibodies against metreleptin appeared.
Report a problemFND-3221364901
02HumanCase report or seriesEfficacy outcome
In a patient with atypical partial lipodystrophy, visceral fat decreased slightly during setmelanotide treatment.
In plain wordsIn a patient with atypical lipodystrophy, visceral fat decreased slightly from before setmelanotide treatment.
Peptide
Setmelanotide
Outcome
DecreaseVisceral fat
Study
n = 1
Comparator
Before setmelanotide
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Although there was a slight decrease in hunger scales and visceral fat, stimulating melanocortin-4 receptor by setmelanotide did not result in any other metabolic benefit such as improvement of hypertriglyceridemia or diabetes control as desired.
1 context sentence(design, population, supporting numbers)
Summary · context
A patient with atypical partial lipodystrophy who had a transient initial response to metreleptin experienced acute worsening of her metabolic state when neutralizing antibodies against metreleptin appeared.
Report a problemFND-3221364902
03HumanCase report or seriesEfficacy outcome
In a patient with atypical partial lipodystrophy, setmelanotide did not improve hypertriglyceridemia.
In plain wordsIn a patient with atypical lipodystrophy, high triglycerides did not improve from before setmelanotide treatment.
Peptide
Setmelanotide
Outcome
No significant changeHypertriglyceridemia
Study
n = 1
Comparator
Before setmelanotide
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Although there was a slight decrease in hunger scales and visceral fat, stimulating melanocortin-4 receptor by setmelanotide did not result in any other metabolic benefit such as improvement of hypertriglyceridemia or diabetes control as desired.
1 context sentence(design, population, supporting numbers)
Summary · context
A patient with atypical partial lipodystrophy who had a transient initial response to metreleptin experienced acute worsening of her metabolic state when neutralizing antibodies against metreleptin appeared.
Report a problemFND-3221364903
04HumanCase report or seriesEfficacy outcome
In a patient with atypical partial lipodystrophy, setmelanotide did not improve diabetes control.
In plain wordsIn a patient with atypical lipodystrophy, diabetes control did not improve from before setmelanotide treatment.
Peptide
Setmelanotide
Outcome
No significant changeDiabetes control
Study
n = 1
Comparator
Before setmelanotide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Although there was a slight decrease in hunger scales and visceral fat, stimulating melanocortin-4 receptor by setmelanotide did not result in any other metabolic benefit such as improvement of hypertriglyceridemia or diabetes control as desired.
1 context sentence(design, population, supporting numbers)
Summary · context
A patient with atypical partial lipodystrophy who had a transient initial response to metreleptin experienced acute worsening of her metabolic state when neutralizing antibodies against metreleptin appeared.
Report a problemFND-3221364904
05HumanCase report or seriesEfficacy outcome
In a patient with atypical partial lipodystrophy, reported food intake decreased mildly during setmelanotide treatment.
In plain wordsIn a patient with atypical lipodystrophy, reported food intake decreased mildly from before setmelanotide treatment.
Peptide
Setmelanotide
Outcome
DecreaseFood intake
Study
n = 1
Comparator
Before setmelanotide
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Although stimulating the MC4R pathway was not sufficient to obtain a significant metabolic benefit in lowering triglycerides and helping with her insulin resistance as was noted with metreleptin earlier, there was a mild reduction in reported food intake and appetite.
1 context sentence(design, population, supporting numbers)
Summary · context
A patient with atypical partial lipodystrophy who had a transient initial response to metreleptin experienced acute worsening of her metabolic state when neutralizing antibodies against metreleptin appeared.
Report a problemFND-3221364905
06HumanCase report or seriesEfficacy outcome
In a patient with atypical partial lipodystrophy, setmelanotide did not provide significant benefit for insulin resistance.
In plain wordsIn a patient with atypical lipodystrophy, insulin resistance did not improve significantly from before setmelanotide treatment.
Peptide
Setmelanotide
Outcome
No significant changeInsulin resistance
Study
n = 1
Comparator
Before setmelanotide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Although stimulating the MC4R pathway was not sufficient to obtain a significant metabolic benefit in lowering triglycerides and helping with her insulin resistance as was noted with metreleptin earlier, there was a mild reduction in reported food intake and appetite.
1 context sentence(design, population, supporting numbers)
Summary · context
A patient with atypical partial lipodystrophy who had a transient initial response to metreleptin experienced acute worsening of her metabolic state when neutralizing antibodies against metreleptin appeared.
Report a problemFND-3221364906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.